Understanding the New FDA QMSR: 21 CFR Part 820 Explained

The FDA's Quality System Regulation under 21 CFR Part 820 has officially become the Quality Management System Regulation (QMSR). The updated rule took effect on February 2, 2026, marking the most significant change to U.S. medical device quality requirements in decades, and it incorporates ISO 13485:2016 by reference rather than restating a parallel U.S.-only framework.

With ISO 13485:2016 now incorporated directly into Part 820, manufacturers who are already ISO 13485 certified will find the transition more manageable — but not automatic. The FDA has retained certain U.S.-specific requirements, including expectations around complaint handling, recordkeeping, and labeling controls, so a straight substitution of your ISO 13485 QMS for the old QSR is not sufficient on its own.

FDA has also shifted how it inspects against the new rule: as of February 2, 2026, investigators use the updated Compliance Program 7382.850, replacing the former 7382.845 and 7383.001 programs. Manufacturers should run a gap assessment comparing their existing documentation against QMSR, confirm their procedures and records are structured for an ISO-aligned inspection, and address any remaining U.S.-specific gaps before their next audit cycle.